Sivelestat

Sivelestat

Systematic (IUPAC) name
N-{2-[({4-[(2,2-dimethylpropanoyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ (Prescription only)
Routes of administration	IV
Identifiers
CAS Number	127373-66-4
ATC code	None
PubChem	CID 107706
IUPHAR/BPS	6441
ChemSpider	96875
UNII	DWI62G0P59
KEGG	D03788
ChEMBL	CHEMBL76688
Chemical data
Formula	C20H22N2O7S
Molar mass	434.46 g/mol
SMILES CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O
InChI InChI=1S/C20H22N2O7S/c1-20(2,3)19(26)29-13-8-10-14(11-9-13)30(27,28)22-16-7-5-4-6-15(16)18(25)21-12-17(23)24/h4-11,22H,12H2,1-3H3,(H,21,25)(H,23,24) Key:BTGNGJJLZOIYID-UHFFFAOYSA-N
(what is this?)  (verify)

Sivelestat (INN, research name ONO 5046, marketed as Elaspol) is an inhibitor of human neutrophil elastase.^[1]

It is used in the treatment of acute respiratory failure^[2] and preliminary studies show it may also improve neuropathic pain.^[3]

Synthesis

Sivelestat is synthesised as follows:^[4]

References

1. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T (June 1991). "ONO-5046, a novel inhibitor of human neutrophil elastase". Biochem. Biophys. Res. Commun. 177 (2): 814–20. doi:10.1016/0006-291X(91)91862-7. PMID 2049103.
2. Imokawa S, Mori K, Harada M, et al. (June 2008). "[Acute respiratory failure due to pneumocystis pneumonia successfully treated with combined use of sivelestat sodium hydrate]". Nihon Kokyuki Gakkai Zasshi (in Japanese) 46 (6): 461–5. PMID 18592991.
3. Weyer, Andy D.; Stucky, Cheryl L. (May 2015). "Repurposing a leukocyte elastase inhibitor for neuropathic pain". Nature Medicine 21 (5): 429–430. doi:10.1038/nm.3861. ISSN 1078-8956.
4. K. Imaki, Y. Arai, T. Okegawa, U.S. Patent 5,017,610 (1991).